Gilead Shares Worth At Least $120 In Takeover By AstraZeneca, Says Piper Jaffray
June 08, 2020 at 07:00 AM EDT
AstraZeneca made a preliminary approach to Gilead Sciences last month regarding a potential merger, Piper Jaffray analyst Tyler Van Buren tells investors in a research note.
